WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Crawford works 6 solid innings and the Red Sox deal the struggling Pirates a 5th straight lossBrice Turang and Jackson Chourio hit backCaballero's tiebreaking double in the 10th lifts Rays past Yankees 2First baseman Nathaniel Lowe back with Rangers after missing first 20 games with oblique strainFirst aid consignment via Cyprus corridor departs for GazaToronto's Nylander out for Game 1 against BruinsSimon Cowell reveals why he wears redInside Tori Spelling's VERY youthful skater girl makeover following divorce from Dean McDermottResidents of four SerbIraq investigates a blast at a base of Iran